BioSpace News Archive

Drug Development

Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program

In SAKURA 3, RT002 was well-tolerated across over 3,800 treatments in glabellar (frown) lines

December 4, 2018
·
15 min read
Business

ForeverGreen Worldwide Corp. Reports Positive Cash Flow and Lower Overhead Costs Leading the way to Profitability

The company’s cost structure and effective cash-flow management contribute to overall financial performance

December 4, 2018
·
2 min read
Chemistree Provides Washington State Operations Update

Chemistree Technology Inc. is pleased to announce the following significant developments as provided by its licensee partner managing the cultivation, processing and delivery to points of sale of the Sugarleaf branded suite of products.

December 4, 2018
·
7 min read
Biotech Bay

New DDN Storage-Powered Technology Platform Delivers Researchers Capability for Real-Time Analysis of High-Rate Microscopy Data

New Solution Delivers 1,600-fold Yield Compared with Traditional Microscopy Workflows

December 4, 2018
·
4 min read
Business

Medidata Rave Omics Collaboration Uncovers Novel Insights for Rare Disease Research

Discovery of biomarker evidence in Castleman Disease exemplifies the value of personalized medicine in rare diseases

December 4, 2018
·
4 min read
Business

Generex Posts Slides, Script & Recording of the December 3, 2018 Investor Conference Call

Slide Deck and transcript available for download

December 4, 2018
·
3 min read
Policy

China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

Fixed-Dose Combination HIV Treatment Backbone Can Be Paired with Range of Third Agents

December 4, 2018
·
8 min read
Biotech Bay

China’s National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the National Medical Products Administration (NMPA) has approved Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) in China for the treatment of chronic hepatitis C virus (HCV) genotype 1-6 infection in adults and adolescents aged 12 to 18 years.

December 4, 2018
·
6 min read
Business

Cerebain Initiates Repositioning and Review of Business and Corporate Strategic Growth Plan

Cerebain Biotech Corp. today announced that it has initiated a repositioning and review of its overall business and corporate strategic plan to maximize shareholder value.

December 4, 2018
·
3 min read
Business

Family Doctor Launches First Virtual Institute to Help Physicians Launch Successful Businesses

Maiysha Clairborne, M.D. Launches First Entrepreneur’s Institute for Physicians

December 4, 2018
·
2 min read